Potassium%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCL) is an electrolyte supplement used to treat or prevent hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment and prevention of hypokalemia. ## Adult Dosing * **Oral:** * **Prevention:** 20 mEq (1.5 g) to 40 mEq (3 g) per day, divided into 1 to 4 doses. * **Treatment:** 40 mEq (3 g) to 100 mEq (7.5 g) per day, divided into 2 to 4 doses. Higher doses may be used cautiously under close monitoring. * Maximum daily dose typically not to exceed 200 mEq (15 g) per day, but this is highly individualized and depends on clinical status and monitoring. * **Intravenous (IV):** * Dosing is highly individualized based on serum potassium levels and patient condition. * **Mild to moderate hypokalemia:** 10 mEq to 20 mEq per hour. * **Severe hypokalemia or rapid correction:** 20 mEq to 40 mEq per hour, but typically infused through a central line to prevent phlebitis. * Maximum infusion rate generally recommended not to exceed 10 mEq to 20 mEq per hour peripherally to avoid pain and phlebitis, and not to exceed 40 mEq per hour centrally to avoid cardiac arrhythmias. * Maximum single dose generally not to exceed 40 mEq (3 g) per dose. * Total daily dose is individualized and guided by serum potassium levels and ECG. ## Pediatric Dosing * **Oral:** * **Maintenance:** 1 mEq/kg/day to 2 mEq/kg/day, not to exceed adult doses. * **Treatment of hypokalemia:** Up to 5 mEq/kg/day to 10 mEq/kg/day, divided into 2 to 4 doses. * **Intravenous (IV):** * Dosing is highly individualized based on serum potassium levels and patient condition. * **General IV replacement:** 0.3 mEq/kg to 0.5 mEq/kg per dose, infused over 1 to 3 hours. * **Severe hypokalemia or rapid correction:** May require higher doses and slower infusion rates, often with continuous ECG monitoring. * Maximum infusion rate generally not to exceed 0.5 mEq/kg/hour, or 20 mEq/hour, whichever is less. Central line preferred for infusions > 0.5 mEq/kg/hour or for concentrations > 40 mEq/L. * Maximum total daily dose typically not to exceed 200 mEq/day. ## Dose Adjustments * No specific dose adjustment for renal impairment is universally established, but caution is warranted. Use the lowest effective dose and monitor potassium levels closely. Dosing often requires careful titration. ## Contraindications * Severe renal impairment with oliguria or azotemia. * Uncorrected hyperkalemia. * Conditions which may predispose to hyperkalemia (e.g., Addison's disease, untreated Addison's disease, crush syndrome, severe burns, extensive tissue injury). * Certain medications that can increase serum potassium (see Drug Interactions). * Gastrointestinal obstruction, delayed gastric emptying, or esophageal compression may increase the risk of gastric or esophageal erosion with oral solid dosage forms. ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain, flatulence (oral). * **Serious:** Hyperkalemia (especially with rapid IV infusion, excessive doses, or in patients with renal impairment), cardiac arrhythmias, cardiac arrest, phlebitis, venous thrombosis (IV), GI ulceration, bleeding, perforation (oral, especially with sustained-release forms). ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene):** Increased risk of hyperkalemia. * **ACE inhibitors (e.g., lisinopril, enalapril) and ARBs (e.g., losartan, valsartan):** Increased risk of hyperkalemia. * **NSAIDs (e.g., ibuprofen, naproxen):** May decrease potassium excretion and increase risk of hyperkalemia. * **Heparin:** May impair potassium excretion and increase risk of hyperkalemia. * **Trimethoprim:** Can have potassium-sparing effects similar to ACE inhibitors. * **Digoxin:** Hyperkalemia can increase digoxin toxicity. Hypokalemia can potentiate digoxin toxicity. ## Monitoring * **Serum potassium levels:** Frequently, especially with IV administration, high oral doses, renal impairment, or concurrent use of interacting medications. * **Renal function:** Monitor BUN and creatinine. * **ECG:** Essential with IV administration, especially for rapid infusions or high doses, to detect changes indicative of hyperkalemia (e.g., peaked T waves, widened QRS complex). * **Signs and symptoms of hypokalemia and hyperkalemia.** ## Clinical Pearls * Oral solid dosage forms (tablets, wax matrix) should be taken with a full glass of water and the patient should remain in an upright position to reduce the risk of esophageal irritation or ulceration. * Liquid formulations are often preferred for patients with swallowing difficulties or to reduce GI irritation. * Sustained-release formulations may offer improved GI tolerance but can also cause GI irritation or obstruction. * IV potassium chloride should always be diluted according to institutional policy. Concentrations greater than 40 mEq/L centrally or 20 mEq/L peripherally are generally not recommended due to increased risk of pain, phlebitis, and cardiac events. * Correcting severe hypokalemia requires careful titration and monitoring due to the risk of cardiac arrhythmias and hyperkalemia. *** *Please verify the current prescribing information for specific details, as this information is intended as a concise overview and may not encompass all possible scenarios or updates.*